| Literature DB >> 36032360 |
Dana Grunhaus1, Estefanía Rossich Molina1, Roni Cohen1, Tamar Stein1, Assaf Friedler1, Mattan Hurevich1.
Abstract
Preparing phosphorylated peptides with multiple adjacent phosphorylations is synthetically difficult, leads to β-elimination, results in low yields, and is extremely slow. We combined synthetic chemical methodologies with computational studies and engineering approaches to develop a strategy that takes advantage of fast stirring, high temperature, and a very low concentration of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to produce multiphosphorylated peptides at an extremely rapid time and high purity.Entities:
Year: 2022 PMID: 36032360 PMCID: PMC9397535 DOI: 10.1021/acs.oprd.2c00164
Source DB: PubMed Journal: Org Process Res Dev ISSN: 1083-6160 Impact factor: 3.858
Figure 1Fmoc deprotection (blue) and β-elimination (red) of protected phosphorylated Ser/Thr are competing reactions that take place under basic conditions. The common deprotection protocol, using 20% piperidine solution, results in complete deprotection at RT while promoting β-elimination at high temperature (right). New conditions are required for minimizing β-elimination during Fmoc deprotection at high temperatures (left).
Screening for Optimal Fmoc Deprotection Conditions at 90 °C
| crude
purity | |||
|---|---|---|---|
| conditions | 5 min | 2 h | |
| I | 0.5% DBU | 96 | 97 |
| II | 0.5% Piperidine | 65 | 77 |
| III | 5% Piperidine | 28 | 83 |
| IV | 1% Piperazine | 84 | 72 |
| V | 10% Morpholine | 67 | 89 |
Incomplete deprotection.
Significant β-elimination.
Determined by HPLC.
Figure 2(A) Potential energy surface (PES) representing Fmoc deprotection (i) and β-elimination (ii) processes with DBU. (B) PES representing Fmoc deprotection (i) and β-elimination (ii) processes using piperidine. The chemical structure associated with the initial, final, and intermediate compounds, annotated i-a to i-c and ii-a to ii-c, are described in the SI. ΔE values are calculated with respect to the initial structures (i-a/ii-a).
Library of Multiphosphorylated Peptides Synthesized in the Current Study
| entry | protein region | sequence | crude purity [%] | yield [%] |
|---|---|---|---|---|
| V2R-5p | V2R (362–371) | pSpSpSLAKDpTpSS | 7.7 | 4.2 |
| APC-4p | APC (1502–1511) | CpS*pS*SLpSALpSL | 31.5 | 27.0 |
| p53–5p | P53 (6–20) | pS*DPpS*VEPPLpSQEpT*FpS* | 19.9 | 6.5 |
| B2R-5p | B2 bradykinin receptor (366–375) | pSMGpT*LR*pT*pSIpS | 13.7 | 12.8 |
| Vim-4p | Vimentin (S22–S29) | pS*R*P*pS*pS*pSRSLLL | 27.8 | 24.0 |
| Tau-6p | Tau (515–527) | pS*pSPGpSPG*pT*PGpS*R*pS*LLL | 12.7 | 3.6 |
| pLam-4p | preLamin A/C (404–411) | pS*HpS*pSQ*pT*QGLLL | 37.2 | 33.6 |
| FFA-5p | Free Fatty Acid receptor 4 (346–360) | L*pT*D*pT*pS*VKRNDLpSIIpS | 14.2 | 6.9 |
The yields were determined by the mass of an isolated pure peptide divided by the mass of a crude peptide. Crude purity was determined by HPLC from the ratio between the peak of the desired MPP and the sum of all other integration peaks.
Peptides with large number of p-sites and/or polar residues were added to a non-native hydrophobic tri-Leu sequence to facilitate purification (blue).
Figure 3B2R-5p synthesis by either the MW-assisted (A) or AMPS (B) approaches. In both syntheses, three residues (marked with *) were coupled twice pSMGpT*LR*pT*pSIpS since the coupling involved an introduction of a bulky pThr or Arg to clustered regions..